Evofem Biosciences to Report Second Quarter 2021 Results and Provide Corporate Update on Wednesday, August 11, 2021

Rhea-AI Summary

Evofem Biosciences, Inc. (NASDAQ: EVFM) will host a webcast and conference call on August 11, 2021, at 4:30 p.m. ET to discuss its financial results for the second quarter ended June 30, 2021. Participants can access the event live and via archived presentation at this link. For phone participation, dial (866) 503-5561 (U.S.) or (253) 336-2965, using conference ID 9190716. An audio replay will be available for 24 hours post-call. Evofem focuses on innovative women's health solutions, including its FDA-approved product Phexxi®.

SAN DIEGO, July 28, 2021 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2021 on Wednesday, August 11, 2021 at 4:30 p.m. ET (1:30 p.m. PT).

The webcast (live and archived) and related slide presentation can be accessed through https://evofem.investorroom.com/2021Q2Results or directly at https://edge.media-server.com/mmc/p/h6zpy9h5. Please connect to the webcast at least 15 minutes prior to the start of the call to download any software that may be required.

If participating by phone, please dial in approximately 15 minutes prior to the start of the call using (866) 503-5561 (U.S. toll-free) or (253) 336-2965, and referring to conference ID 9190716.

A telephone replay will be available for 24 hours after the call at (855) 859-2056 (U.S.) or (404) 537-3406 (International), conference ID 9190716.

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company launched its first FDA-approved commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), in the United States in September 2020. The Company is evaluating lead product candidate EVO100 for the prevention of urogenital Chlamydia trachomatis and  Neisseria gonorrhoeae infection in women in the ongoing Phase 3 clinical trial, 'EVOGUARD.' For more information, please visit evofem.com.

Phexxi^® is a registered trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-report-second-quarter-2021-results-and-provide-corporate-update-on-wednesday-august-11-2021-301342050.html

SOURCE Evofem Biosciences, Inc.

FAQ

When is Evofem Biosciences' Q2 2021 earnings call?

Evofem Biosciences' Q2 2021 earnings call is on August 11, 2021, at 4:30 p.m. ET.

How can I access the Evofem Biosciences Q2 2021 results webcast?

You can access the Evofem Biosciences Q2 2021 results webcast at this link: https://evofem.investorroom.com/2021Q2Results.

What is the conference ID for Evofem Biosciences' earnings call?

The conference ID for Evofem Biosciences' earnings call is 9190716.

What products does Evofem Biosciences offer?

Evofem Biosciences offers innovative products for women's health, including the FDA-approved contraceptive Phexxi®.

What is the purpose of the upcoming Evofem Biosciences conference call?

The conference call is to discuss financial results and business highlights for the second quarter ended June 30, 2021.